Amneal Takes A Step Forward On Biosimilars

FDA Accepts Filing For Bevacizumab Rival To Avastin, Partnered With Mabxience

 
• By David Wallace
  
Wooden blocks 2021, 2022, 2023
Amneal plans to build up its biosimilars business with a launch every year to 2023 • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products